AGOURA HILLS, Calif., July 13, 2020 (GLOBE NEWSWIRE) — Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today that it will fund observational studies for Artemisinin, an herbal supplement, that demonstrated potent in vitro activity against SARS-CoV-2, the COVID-19 virus. By collecting data from multiple clinical observational studies globally, the company expects to establish Artemisinin efficacy against COVID-19 as an affordable front-line treatment for this pandemic in low resources countries.
News Ticker
- [ December 6, 2023 ] CatalYm’s efforts to revive obesity target for solid tumors yield positive PhIIa results Los Angeles Biotech News
- [ December 6, 2023 ] Latino Alternative Television (LATV) Partners with the Huntsman Mental Health Institute and the Ad Council for Latino Men’s Mental Health Event Los Angeles Biotech News
- [ December 6, 2023 ] Deep 6 AI Expands Its Recruitment Acceleration Solution for Life Sciences to Shorten the Time from Determining Patient Eligibility to Enrollment Los Angeles Biotech News
- [ December 6, 2023 ] Lab operation Manager – MolBreeding biotechnology LLC – Irvine, CA Los Angeles Biotech Jobs
- [ December 6, 2023 ] SaniSure earns EcoVadis Silver Rating, recognizing strong commitment to sustainability Los Angeles Biotech News
Copyright © 2023 Biotech Networks, LLC
